Can-Fite BioPharma (CANF) New Positive Data from its Liver Cancer Phase II Clinical Study with Namodenoson
Go back to Can-Fite BioPharma (CANF) New Positive Data from its Liver Cancer Phase II Clinical Study with Namodenoson| CAN-FITE BIOPHARMA LTD. (NYSE: CANF) | Delayed: 1.94 -0.03 (1.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.97 | 52 Week High | $3.89 | |||
| Open | $1.96 | 52 Week Low | $1.85 | |||
| Day High | $1.96 | P/E | N/A | |||
| Day Low | $1.93 | EPS | $0.00 | |||
| Volume | 5,741 | |||||
| (NASDAQ: CFBI) | Delayed: 10.08 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.08 | 52 Week High | $ | |||
| Open | $41.64 | 52 Week Low | $ | |||
| Day High | $10.08 | P/E | N/A | |||
| Day Low | $10.08 | EPS | $ | |||
| Volume | 206 | |||||
